Cytomegalovirus (CMV) disease remains a major cause of morbidity following allogeneic stem cell transplantation (SCT). In a prospective randomized trial, we tested prophylactic therapy with ganciclovir or acyclovir for patients at high risk of disease. Ninety-one CMV seropositive recipients of related (n = 53) and unrelated (n = 38) donor transplants were enrolled. All patients received intravenous (i.v.) ganciclovir 5 mg/kg every 12 h days ؊7 to ؊2, followed by acyclovir 10 mg/kg i.v. every 8 h from day ؊1 until neutrophil engraftment. Patients were then randomly assigned to either ganciclovir (n = 45) or acyclovir (n = 46) until day 100 post transplant. Any degree of antigenemia was treated with ganciclovir 5 mg/kg i.v. twice a day for 2 weeks, followed by 5 mg/kg i.v. each weekday for 6 weeks. At day 100, the cumulative incidence of antigenemia was 31% (95% CI 17-45%) for ganciclovir and 41% (95% CI 26-56%) (P = 0.22) for acyclovir prophylaxis, respectively. The assigned prophylaxis cohort did not predict for CMV antigenemia. The cumulative incidence of CMV disease at 12 months was 13% (95% CI 3-23%) and 17% (95% CI 6-28%) (P = 0.59) for the ganciclovir-and acyclovir-treated groups, respectively. An absolute neutrophil count (ANC) р1500 ؋ 10 6 /l at randomization (P < 0.01) and grade II-IV acute graftversus-host-disease (P = 0.01), but not the assigned prophylaxis cohort (P = 0.62), were independent risk factors for CMV disease. The incidence of fungal infections and renal insufficiency was similar across treatment groups; however, bacterial infections and secondary neutropenia occurred more frequently in the ganciclovir group. With our study powered to detect a 60% reduction in antigenemia with ganciclovir prophylaxis, we did not find a statistically significant difference between ganciclovir and acyclovir when used as part of an overall strategy for prevention of CMV antigenemia and disease in SCT, although fewer side-effects occurred with acyclovir treatment.
1,2
CMV seropositive recipients are at a high risk of CMV disease, as reactivation of latent endogenous virus is the dominant mechanism of infection in immunocompromised patients. [1] [2] [3] [4] [5] Despite recent advances in therapy, the mortality from CMV disease, and particularly CMV pneumonia, remains quite high. Recent therapeutic strategies have focused on the prevention of CMV disease.
Acyclovir and ganciclovir have each been shown to be effective prophylaxis for patients at high risk of CMV disease. Two prospective studies demonstrated a decrease in the occurrence of CMV disease as well as a survival benefit of high-dose acyclovir for allogeneic marrow transplant recipients. [5] [6] [7] Ganciclovir has been incorporated into various prophylactic strategies. [8] [9] [10] [11] [12] [13] [14] [15] In each of three randomized studies, [8] [9] [10] ganciclovir prophylaxis decreased CMV infection and/or disease; however, there was no benefit in overall survival.
This study was designed to test whether prophylactic ganciclovir is superior to high-dose acyclovir, when ganciclovir is used pre-emptively at first evidence of active CMV replication, in a prospective, randomized study. We report an analysis of the incidence of CMV antigenemia measured at 100 days post transplant and CMV disease, in addition to a comparison of the frequency of complications by prophylactic therapy.
Materials and methods

Patients
Ninety-one CMV seropositive recipients of related (n = 53) and unrelated (n = 38) donor SCT were enrolled, irrespective of donor CMV status. All patients were first-time transplant recipients. HLA (human leukocyte antigen matching) was determined by A, B serology and DRB high-resolution techniques. Data regarding the pre-transplantation characteristics, post-transplantation complications, and survival were collected prospectively by the Biostatistics Support Group at the University of Minnesota using standardized methods. Details of CMV therapy and clinical outcomes were obtained from a review of patients' medical records.
Protocol design
As shown in Figure 1 , all patients received intravenous (i.v.) ganciclovir 5 mg/kg every 12 h days Ϫ7 to Ϫ2, followed by acyclovir 10 mg/kg i.v. every 8 h from day Ϫ1 until neutrophil engraftment (absolute neutrophil count (ANC) у750 ϫ 10 6 /l for 2 consecutive days). Patients were then randomly assigned, with stratification for related vs unrelated donor transplant, to either acyclovir 800 mg (adults) or 18 mg/kg (children) orally 5 times a day (n = 46) or ganciclovir 5 mg/kg i.v. every weekday (Monday to Friday) (n = 45) until day 100. All patients received i.v. immunoglobulin (IVIg) 500 mg/kg on days Ϫ6, 0, 7, 21, 35, 55, 76 and 98. All patients had CMV serology tested within 4 weeks prior to transplantation. Donor CMV serology was tested before blood stem cell or bone marrow harvest. The Institutional Review Board of the University of Minnesota approved the trial, and all enrolled patients or their legal guardians gave written informed consent.
Supportive care
Patients who developed an ANC of <750 ϫ 10 6 /l but > 500 ϫ 10 6 /l during prophylactic therapy were treated with granulocyte colony-stimulating factor (G-CSF) at a dose of 5 g/kg/day and continued receiving the assigned CMV prophylaxis. If the ANC fell to <500 ϫ 10 6 /l, prophylaxis was discontinued until recovery to >750 ϫ 10 6 /l, then restarted with continued G-CSF support. Patients received ongoing oral prophylaxis for bacterial infections (penicillin V potassium 250 mg twice daily), fungal infections (fluconazole 200 mg daily), and Pneumocystis carinii pneumonia (trimethoprim-sulfamethoxazole, one doublestrength tablet twice daily every Monday and Tuesday). ganciclovir 5 mg/kg every 12 h days Ϫ7 to Ϫ2, followed by acyclovir 10 mg/kg i.v. every 8 h from day Ϫ1 until absolute neutrophil count (ANC) у750 ϫ 10 6 /l for 2 consecutive days. Patients were then randomly assigned, with stratification for type of transplant, to either ganciclovir 5 mg/kg i.v. Monday to Friday (n = 45) or acyclovir 800 mg (adults) or 18 mg/kg (children) orally five times a day (n = 46) until day +100.
CMV surveillance
Antigenemia assays were performed weekly from day 0 to day 100 post transplant. The assay was done using a commercial kit (CMV-Vue: Incstar, Stillwater, MN, USA) according to the manufacturer's instructions. Standard methods were used for isolation of CMV from bronchoalveolar lavage fluid and tissue samples, as previously described. 15 
CMV therapy
With any degree of antigenemia (у1 positive cell/50 000 leukocytes), prophylaxis was discontinued and patients were treated pre-emptively with an induction dose of ganciclovir 5 mg/kg i.v. twice daily for 2 weeks, followed by 5 mg/kg i.v. every weekday for 6 weeks. If antigenemia recurred during or after the maintenance phase, induction with twice daily ganciclovir was restarted and was again followed by 6 weeks of maintenance therapy. Foscarnet was given to patients whose antigenemia did not resolve with ganciclovir therapy. All patients in whom CMV disease was diagnosed were treated with the same schedule and duration of ganciclovir, with the addition of IVIg 500 mg/kg on alternate days for 2 weeks, then twice a week for another 4 weeks. If disease recurred during the maintenance phase, induction was restarted.
Definitions
CMV antigenemia: one or more positive cells per 50 000 (or fewer) leukocytes examined. Recurrent antigenemia was defined as any degree of antigenemia occurring following complete resolution of antigenemia as a result of preemptive ganciclovir therapy; persistent antigenemia was defined as failure to resolve CMV antigenemia with preemptive ganciclovir therapy. CMV disease: signs/symptoms of disease in conjunction with culture of CMV (by conventional or shell-vial technique) from visceral tissue or cerebrospinal fluid, or pathologic changes of CMV in biopsy tissue. CMV pneumonia was defined as interstitial infiltrates on chest radiograph accompanied by histologic demonstration of CMV in lung biopsy material or a positive CMV culture from bronchoalveolar lavage fluid. CMV gastroenteritis was defined as gastrointestinal symptoms accompanied by histologic demonstration of CMV or a positive CMV culture from biopsy material obtained by endoscopy. Early CMV disease was defined as disease occurring prior to day 100 post transplant; late CMV disease as disease occurring after day 100. CMV related death: death occurring within 6 weeks of the diagnosis of CMV disease in which CMV disease was clinically felt to be a contributing cause.
Statistical analysis
Prestudy sample size and power projections: The study was designed as a prospective randomized trial. The primary endpoint of the study was the incidence of CMV antigenemia at day 100. To detect a 60% reduction in antigenemia with ganciclovir prophylaxis (assuming a 50% incidence in the acyclovir arm) with 80% power at ␣ of 0.05, a sample size of 90 patients (half randomized to each arm) was needed. The assumed incidence in the acyclovir arm was based on our own institutional experience and the incidences of CMV infection reported in previously published studies of acyclovir prophylaxis, [5] [6] [7] recognizing the differences in study design, patient population, method of CMV detection, and statistical analysis of outcomes. Secondary endpoints included CMV disease, survival and complications related to prophylactic therapy.
Antigenemia and disease: the cumulative incidence of antigenemia and disease were calculated by treating deaths from other causes as competing risks. 16 Univariate comparisons of the impact of study variables on antigenemia and disease were determined by the Mantel-Cox log-rank test. Study variables included age, diagnosis, donor CMV serostatus, type of transplant (related vs unrelated matched donor vs unrelated mismatched donor), days from transplant to randomization, graft-versus-host disease (GVHD) prophylaxis (methotrexate/cyclosporine vs T cell depletion by elutriation), grade II-IV acute GVHD, as well as hemoglobin (>10 vs р10 g/dl), white blood cell (WBC) (>2500 versus р2500 ϫ 10 6 /l), ANC (>1500 vs р1500 ϫ 10 6 /l) and creatinine (<1.5 vs у1.5 mg/dl) at time of randomization. The independent effect of study variables was analyzed using Cox proportional hazards regression models. All factors were tested for the proportional hazards assumption. Acute GVHD was treated as a time-dependent variable in these models.
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Survival: Patient survival was determined using the Kaplan-Meier method 18 with 95% confidence intervals derived from standard errors. Patients were censored at the date of last contact. Comparison of survival between the two treatment groups was carried out using Kaplan-Meier plots and log-rank tests. 18 
Complications of prophylactic therapy
Complications studied included secondary neutropenia (defined as ANC Ͻ750 ϫ 10 6 /l following initiation of prophylactic therapy), renal insufficiency (defined as creatinine у15 mg/dl for patients with a creatinine <1.5 mg/dl at randomization, or as у3 mg/dl for patients with creatinine of 1.5-3 mg/dl at randomization), and infections. The cumulative incidence of complications was calculated by treating deaths from other causes as competing risks. 16 To account for multiple events, incidence density was used to describe the total rate of infections. Incidence density was defined as the total number of infections per 1000 patientdays. Confidence intervals for these rates were determined by assuming a Poisson distribution for the number of infections. A corresponding P-value was calculated from the Mantel-Haenzsel chi-square test for person-years data. 19 MDS = myelodysplastic syndrome; CML = chronic myelogenous leukemia; URD = unrelated donor; Bu = busulfan; Cy = cyclophosphamide; TBI = total body irradiation; TLI = total lymphoid irradiation; GVHD = graft-versus-host disease; MTX = methotrexate; CsA = cyclosporine.
Results
istics were similar between treatment groups, including CMV serology and time from transplant to randomization.
CMV antigenemia
Thirty-three (36%) of the 91 patients developed CMV antigenemia before day 100 post-transplant ( Table 2 ). The cumulative incidence of CMV antigenemia was 31% (95% CI 17-45) with ganciclovir prophylaxis compared with a 41% incidence (95% CI 26-56) with high-dose acyclovir. The median number of days to antigenemia was similar by treatment, as was the median level of antigenemia. We further evaluated the effect of treatment group within strata of various pre-treatment study variables and did not find a differing risk of antigenemia, except for an increased risk in patients у18 years of age who received acyclovir prophylaxis. At day 100, 14 of 29 (48%, 95% CI 33-63%) acyclovir-treated patients у18 years of age compared with eight of 30 (27%, 95% CI 13-41%) (P = 0.04) ganciclovirtreated patients developed antigenemia. Multiple regression analysis did not identify any independent risk factors for antigenemia or show any confounding of the effect of prophylactic treatment. 0-14) ) 0.12 n (% (95% CI))
The incidence of recurrent or persistent antigenemia requiring a second course of therapy with ganciclovir and/or foscarnet was similar between groups, although there was a trend towards a higher incidence in the acyclovir treated group. Eight of 46 (17%) patients who received acyclovir prophylaxis developed recurrent or persistent CMV antigenemia; three of 45 (7%) patients who received ganciclovir prophylaxis required additional therapy (P = 0.12) ( Table 2) .
CMV disease
Of the 91 patients, 14 developed CMV disease with a cumulative incidence of 14% (95% CI 7-21%) at 1 year. Of these 14 patients, eight received acyclovir and six received ganciclovir prophylaxis. As shown in Table 3 , there was no difference in the incidence of early or late CMV disease by treatment. In addition, there was no difference in the median time to development of disease (for acyclovir, 2.7 months; ganciclovir 3.1 months). Sites of disease were similar between the two groups. Of the eight patients who received acyclovir prophylaxis and developed recurrent or persistent antigenemia, six (75%) ultimately developed CMV disease. Each of the three patients who received ganciclovir prophylaxis and developed recurrent or persistent antigenemia developed CMV disease.
Univariate comparisons of the impact of study variables on CMV disease demonstrated that lower WBC (P < 0.01) and ANC (P < 0.01) at time of randomization were the most important factors associated with CMV disease. Multiple regression analysis identified ANC р1500 ϫ 10 6 /l at time of randomization (P < 0.01), grade II-IV acute GVHD (P = 0.01), and a trend towards unrelated mismatched donor (0.08), but not the assigned prophylaxis cohort (P = 0.62), as independent risk factors for CMV disease (Table 4) . Table 5 demonstrates the toxicity associated with each regimen. The incidence density of bacterial infections, but not fungal, was greater in the ganciclovir-treated group (12.4 per 1000 patient-days vs 8.0 per 1000 patient-days; P = 0.05). Secondary neutropenia developed in 18 of 46 patients (39%) who received acyclovir prophylaxis, vs 32 of 45 (71%) who received ganciclovir (P = 0.03). Of the 18 acyclovir-treated patients who developed neutropenia, only seven (39%) did so while receiving acyclovir. The remaining patients developed neutropenia after identification of antigenemia or CMV disease that necessitated Table 5 Toxicities of prophylactic treatment Renal insufficiency defined as creatinine у1.5 mg/dl for patients with a creatinine <1.5 mg/dl at randomization, or as у3 mg/dl for patients with creatinine of 1.5-3 mg/dl at randomization. d Cumulative incidence (%) and 95% confidence intervals (CI) are shown. ganciclovir therapy. Of the patients randomized to ganciclovir prophylaxis who developed secondary neutropenia, 26 of the 32 (81%) developed secondary neutropenia while receiving prophylactic doses of ganciclovir, with the remainder developing neutropenia after a change to therapeutic doses following the identification of CMV antigenemia or disease. There was no difference in the overall incidence of renal insufficiency between the two regimens.
Toxicity
Reasons for removal from assigned prophylaxis
The assigned prophylaxis was discontinued and ganciclovir therapy instituted for any degree of antigenemia or disease.
One patient assigned to ganciclovir prophylactic therapy was switched to acyclovir when secondary neutropenia was severe and not responsive to interruption of ganciclovir and growth factor support. An additional patient randomized to ganciclovir was switched to acyclovir when ganciclovir was temporarily unavailable for use.
Survival
There was no statistically significant difference between treatment groups in overall survival at 1 year, with 64% (95% CI 50-78%) ganciclovir recipients and 54% (95% CI 40-68%) (P = 0.38) acyclovir recipients surviving ( Figure 2 ). Univariate comparisons of the impact of study variables demonstrated that the type of transplant (related vs unrelated donor) was the most important factor associated with survival (P = 0.05). We next examined factors associated with survival in multiple regression analysis. As the type of transplant violated the proportional hazards assumptions, the regression model was stratified for related vs unrelated donor transplantation. Age у18 was the only independent risk factor for survival associated with a higher relative risk of death of 2.2 (95% CI 1.0-4.6) (P = 0.05). Prophylactic treatment with ganciclovir was not an independent significant risk factor for survival with a relative risk of death of 0.8 (95% CI 0.4-1.5) (P = 0.50), and showed no interaction with age or other potentially significant variables. There were three CMV-related deaths in the acyclovir group, and one in the ganciclovir-treated group (P = 0.32). Bone Marrow Transplantation
Discussion
The first prospective study of antiviral prophylaxis of CMV in transplant recipients was with acyclovir, as reported by Meyers et al. 5 Intravenous acyclovir prophylaxis decreased and delayed the risk of both CMV infection and disease, and was associated with significantly improved survival. In a second study by Prentice et al, 6, 7 CMV seropositive recipients or recipients of a seropositive graft were randomized to receive one of three acyclovir prophylactic regimens differing by route and dose of administration. Intravenous acyclovir significantly reduced the risk of CMV infection, confirming the results of Meyers et al. 5 In addition, the sequential use of i.v. acyclovir followed by oral acyclovir resulted in a survival advantage of 1 year. 5, 6 Over the past decade, ganciclovir has been incorporated into prophylactic and/or pre-emptive treatment strategies for CMV seropositive patients with demonstrated success. 8, 9, 11, 13 Two prospective, randomized studies showed that ganciclovir was effective in reducing CMV infection and disease when given at time of engraftment to CMV seropositive allogeneic transplant recipients. 8, 9 Goodrich et al 8 reported a trial of 64 patients who received high-dose i.v. acyclovir until engraftment, at which time patients were randomized to ganciclovir or placebo until day 100. By extending antiviral prophylaxis with ganciclovir, the incidence of CMV infection was reduced from 45% to 3%, and that of disease from 29% in the placebo group to none in the ganciclovir group. Winston et al 9 demonstrated that when ganciclovir was given prior to transplantation, then restarted at engraftment, the incidence of CMV infection was reduced from 43% in the placebo group to 20% in the ganciclovir-treated group. In an historically controlled study, CMV seropositive patients were given ganciclovir pretransplant from day Ϫ10 to day Ϫ4, followed by highdose i.v. acyclovir from 3 days pre-transplant to 29 days post transplant, then i.v. ganciclovir until day 90. 13 The historical control group received i.v. acyclovir alone. The ganciclovir-treated patients had a significantly reduced risk of CMV antigenemia, infection and disease.
More recently, Boeckh et al 10 reported results of a prospective, randomized study designed to determine whether CMV antigenemia-guided ganciclovir therapy was as effective as ganciclovir administered at engraftment. Compared to antigenemia-guided therapy, ganciclovir at engraftment was associated with more CMV disease occurring after day 100 and more early invasive fungal infections. These same investigators performed a retrospective analysis comparing these two groups of randomized patients to a third group of patients who had received i.v. acyclovir 500 mg/m 2 every 8 h from day 5 before transplant until engraftment followed by ganciclovir until day 100. The incidence of CMV disease and CMV-related mortality was similar between the groups, leading the authors to conclude that high-dose acyclovir does not improve survival when ganciclovir is given either at engraftment or for antigenemia. 20 As none of these published studies included a direct comparison of acyclovir to ganciclovir, we designed our study to determine whether i.v. ganciclovir could reduce the incidence of CMV antigenemia observed with high-dose acyclovir by 60%. We assumed that 50% of patients would reactivate CMV with high-dose acyclovir prophylaxis. We actually observed a 41% cumulative incidence of CMV antigenemia with high-dose acyclovir and 31% with ganciclovir prophylaxis, a 10% absolute difference. This compares with a reported 41% and 79% incidence of antigenemia in similar patients randomized to receive ganciclovir prophylaxis and placebo, respectively. 10 To detect a 10% difference in the incidence of antigenemia with 70% power and a type I error rate of 5% would have required a sample size of 310 patients, with 155 per treatment arm.
Several aspects of our study may have contributed to the observed outcomes, including the incorporation of eight doses of IVIg to day 98. Immunoglobulin has been shown to modify the severity of CMV infection and prevent interstitial pneumonia, and possibly GVHD in allogeneic recipients. 21 The pre-emptive strategy we used that included both treatment of low-grade antigenemia as well as continuing ganciclovir therapy for a minimum of 8 weeks may also have contributed to the relatively low incidence of CMV disease we observed in both treatment arms. Others have demonstrated that delaying treatment until high-grade antigenemia or discontinuing ganciclovir early after antigenemia resolves can be detrimental to success. 10, 22 Several factors have been associated with the development of CMV disease after transplantation including CMV positive serostatus before transplant, increased age, T cell depletion, post-transplant immunosuppression, acute GVHD and its treatment, total body irradiation in conditioning regimens, and unrelated or mismatched donors.
1,2,23-25 The current study confirmed that patients who develop acute GVHD are at increased risk for CMV disease, and demonstrated also that early neutropenia may be a risk factor, perhaps as a hallmark of delayed immune recovery of effective antiviral surveillance. Similar to the results reported by Foot et al, 25 we saw no difference in CMV disease between allogeneic recipients of related vs unrelated transplants. Although there was a trend towards an increased risk following unrelated donor mismatch transplantation, the number of patients receiving such transplants was quite small. We earlier reported that T celldepleted marrow was associated with an increased risk for CMV disease in patients who did not receive anti-viral prophylactic therapy. 23 In this study, we saw no association with T cell depletion and either CMV antigenemia or disease, confirming a more recent analysis of patients undergoing transplantation at our center who routinely received anti-viral prophylaxis. 26 The most common manifestations of CMV disease, pneumonia and gastroenteritis, typically occur 45 to 60 days after transplantation. 27 During the past few years, CMV disease has been increasingly diagnosed late after transplantation. 10, 28, 29 It has been suggested that the late onset of CMV disease may be due to the use of ganciclovir prophylaxis, which delays recovery of CMV-specific T cell immunity. 30 In our study, the incidence of CMV disease was small in each treatment arm, with similar incidences before and after day 100. This finding of no apparent increase in incidence of late onset CMV disease may be secondary to the different schedule of administration of the maintenance ganciclovir -each weekday instead of daily as in other reported studies. 10, 28, 29 Secondary neutropenia was a significant toxicity of ganciclovir therapy in our study, confirming reports by other investigators. [8] [9] [10] 31 Ganciclovir-induced neutropenia has been associated with increased rates of bacterial sepsis and invasive fungal infections in marrow transplant recipients, as well as mortality. 8, 10, 31 Although we observed more frequent bacterial infections in the ganciclovir-treated group, the rate of fungal infections was similar, which may in part be attributed to our use of prolonged fungal prophylaxis.
The small patient numbers in this study make it very difficult to draw definitive conclusions on the observed difference of 10% between the two treatments. Prophylactic ganciclovir, administered in conjunction with pre-emptive therapy for any degree of CMV antigenemia, may reduce the incidence of CMV antigenemia compared to high-dose acyclovir. However, a much larger study would be needed to confirm the absolute difference of 10% we observed. Alternatively, our data suggest that high-dose oral acyclovir, an easily administered, less expensive drug with fewer side-effects compared to ganciclovir, is efficacious as CMV prophylaxis in this setting of pre-emptive therapy with an acceptable low incidence of CMV disease. Valacyclovir, an oral prodrug of acyclovir, has been shown in a prospective, randomized trail to be more effective than acyclovir in preventing CMV reactivation with a similar incidence of CMV disease. 32 Other antiviral drugs, including foscarnet, cidofovir and valganciclovir are also being studied for prevention of CMV disease. [33] [34] [35] [36] As prophylactic and early treatment strategies aimed at further reduction of CMV antigenemia and disease are developed and tested, consideration should be given to comparison with high-dose acyclovir or valacyclovir in study designs.
